The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical
practice represented a major change in the treatment of non-valvular atrial fibrillation …

Aims: Non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists
(VKAs) are used to prevent stroke in patients with atrial fibrillation (AF). This paper aimed to …

Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …

Objectives Several studies have evaluated the economic evaluation of a group of
medications known as novel oral anticoagulant drugs (NOACs) in recent years. The aim of …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Approximately 250,000 Canadians are affected by atrial fibrillation (AF). Stroke is a
complication of AF, and Canadians with AF are five times more likely to have a stroke and …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …

Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …

Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …